Home » Stocks » STSA

Satsuma Pharmaceuticals, Inc. (STSA)

Stock Price: $4.55 USD -0.13 (-2.78%)
Updated November 30, 2:23 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 79.27M
Revenue (ttm) n/a
Net Income (ttm) -45.89M
Shares Out 17.42M
EPS (ttm) -11.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $4.55
Previous Close $4.68
Change ($) -0.13
Change (%) -2.78%
Day's Open 4.65
Day's Range 4.37 - 4.65
Day's Volume 306,668
52-Week Range 3.56 - 34.69

More Stats

Market Cap 79.27M
Enterprise Value 686,065
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 17.42M
Float n/a
EPS (basic) 1.92
EPS (diluted) -11.20
FCF / Share -2.40
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 812,554
Short Ratio 2.33
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 0.98
Revenue n/a
Operating Income -47.12M
Net Income -45.89M
Free Cash Flow -41.75M
Net Cash 78.59M
Net Cash / Share 4.51
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -26.80%
ROE -45.64%
ROIC -60.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 1
Overweight 0
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Hold

Price Target

(-1.10% downside)
Current: $4.55
Target: 4.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-28.88-7.52-4.95
Net Income-28.18-7.35-5.17
Shares Outstanding5.861.030.56
Earnings Per Share-4.80-7.15-9.26
Operating Cash Flow-29.64-6.98-4.32
Capital Expenditures-0.55-0.40-0.06
Free Cash Flow-30.19-7.38-4.38
Cash & Equivalents1085.211.66
Total Debt4.934.970.09
Net Cash / Debt1030.241.56
Book Value115-12.13-5.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Satsuma Pharmaceuticals, Inc.
Country United States
Employees 17
CEO John A. Kollins

Stock Information

Ticker Symbol STSA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: STSA
IPO Date September 13, 2019


Satsuma Pharmaceuticals, a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.